139 results on '"Spiteri G."'
Search Results
2. The resurgence of syphilis in high-income countries in the 2000s : a focus on Europe
- Author
-
Spiteri, G., Unemo, M., Mårdh, O., and Amato-Gauci, A. J.
- Published
- 2019
Catalog
3. Factors Associated with SARS-CoV-2 Infection before Vaccination among European Health Care Workers
- Author
-
Mansour, I., Godono, A., Sansone, E., Visci, G., Spiteri, G., Monaco, M. G. L., Mates, D., Rascu, A., Duval, X., Pira, E., Ciocan, C., Violante, F., Lodi, V., De Palma, G., Sala, E., Dell'Omo, M., Negro, C., Casolari, L., Abedini, M., Ditano, G., Asafo, S., and Boffetta, P. more...
- Subjects
HCWs ,Mask ,Multicentric ,Meta-analyses ,COVID-19 ,FFP2 ,Determinants - Published
- 2023
4. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021
- Author
-
Funk T., Pharris A., Spiteri G., Bundle N., Melidou A., Carr M., Gonzalez G., Garcia-Leon A., Crispie F., O'Connor L., Murphy N., Mossong J., Vergison A., Wienecke-Baldacchino A. K., Abdelrahman T., Riccardo F., Stefanelli P., Di Martino A., Bella A., Lo Presti A., Casaca P., Moreno J., Borges V., Isidro J., Ferreira R., Gomes J. P., Dotsenko L., Suija H., Epstein J., Sadikova O., Sepp H., Ikonen N., Savolainen-Kopra C., Blomqvist S., Mottonen T., Helve O., Gomes-Dias J., Adlhoch C., Macori G., Russell L., Yandle Z., Bennett C., O'Byrne E., Murphy A., Tuite G., Conroy A., Duffy M., Morley U., Keoghan B., Ford I., Kennedy M., McDonnell S., Flynn A., Clarke A., Crowley A., Martin C., Kelly E., Foxton J., Hare D., Dunford L., Connell J., Moran J., Dean J., Fanning S., Rajan L., De Gascun C., Kenny J., Cotter P., Walsh C., Lawton E., Fitzpatrick A., Mullins E., Della Bartola M., McCabe M., Stapleton P., Meaney C., Fanning L., Prentice M., MacSharry J., Dempsey C., Mallon P., Leon A., Chaturvedi A., Coughlan S., McAndrew G., Reddington K., Walsh F., Fitzpatrick D., Smyth C., O'Dwyer T., Chambers T., Clarke L., Jebb D., Klopp J., Kavanagh D., Haslam K., Buckley P., Lemass K., Fitzpatrick F., Burns K., Cafferkey J., Richmond A., Foley M., Sanchez-Morgado J., Chalapati S., Pinnamaneni N., Crosbie C., Limbachiya D., Tinago W., Garcia Leon A. A., Miles S., Alalwan D., Negi R., Macken A., Feeney E., Kenny G., McCann K., Kelly N., Blair M., McCann R., Kenny C., O'Brion C., Waqas S., Savinelli S., Doran P., Bracken T., Varghese P., Lambert J. S., Cotter A., Muldoon E., Sheehan G., McGinty T., Lambert J., Green S., Leamy K., de Barra E., McConkey S., Kelly C., Horgan M., Sadlier C., Yousif O., O'Donnell J., Fitzgerald M., Petty-Saphon N., Cuddihy J., Fiore S., Fabiani C., Benedetti E., Di Mario G., Facchini M., Puzelli S., Calzoletti L., Fontana S., Venturi G., Fortuna C., Marsili G., Amendola A., Stuppia L., Savini G., Picerno A., Lopizzo T., Dell'Edera D., Minchella P., Greco F., Mauro M. V., Viglietto G., Atripaldi L., Limone A., D'Agaro P., Licastro D., Marcello A., Capobianchi M. R., Icardi G., Bruzzone B., Lillo F., Orsi A., Pariani E., Baldanti F., Gismondo M. R., Maggi F., Caruso A., Ceriotti F., Boniotti B., Bagnarelli P., Garofalo S., Scutella M., Pagani E., Collini L., Ghisetti V., Ru G., Chironna M., Parisi A., Rubino S., Serra C., Piras G., Coghe F., Vitale F., Tramuto F., Scalia G., Palermo C. I., Mancuso G., Di Gaudio F., Vullo S., Reale S., Cusi M. G., Rossolini G. M., Pistello M., Mencacci A., Camilloni B., Severini S., Di Benedetto M., Calogero T., Monne I., Biscaro V., COVID Study Groups, Funk T., Pharris A., Spiteri G., Bundle N., Melidou A., Carr M., Gonzalez G., Garcia-Leon A., Crispie F., O'Connor L., Murphy N., Mossong J., Vergison A., Wienecke-Baldacchino A.K., Abdelrahman T., Riccardo F., Stefanelli P., Di Martino A., Bella A., Lo Presti A., Casaca P., Moreno J., Borges V., Isidro J., Ferreira R., Gomes J.P., Dotsenko L., Suija H., Epstein J., Sadikova O., Sepp H., Ikonen N., Savolainen-Kopra C., Blomqvist S., Mottonen T., Helve O., Gomes-Dias J., Adlhoch C., Macori G., Russell L., Yandle Z., Bennett C., O'Byrne E., Murphy A., Tuite G., Conroy A., Duffy M., Morley U., Keoghan B., Ford I., Kennedy M., McDonnell S., Flynn A., Clarke A., Crowley A., Martin C., Kelly E., Foxton J., Hare D., Dunford L., Connell J., Moran J., Dean J., Fanning S., Rajan L., De Gascun C., Kenny J., Cotter P., Walsh C., Lawton E., Fitzpatrick A., Mullins E., Della Bartola M., McCabe M., Stapleton P., Meaney C., Fanning L., Prentice M., MacSharry J., Dempsey C., Mallon P., Leon A., Chaturvedi A., Coughlan S., McAndrew G., Reddington K., Walsh F., Fitzpatrick D., Smyth C., O'Dwyer T., Chambers T., Clarke L., Jebb D., Klopp J., Kavanagh D., Haslam K., Buckley P., Lemass K., Fitzpatrick F., Burns K., Cafferkey J., Richmond A., Foley M., Sanchez-Morgado J., Chalapati S., Pinnamaneni N., Crosbie C., Limbachiya D., Tinago W., Garcia Leon A.A., Miles S., Alalwan D., Negi R., Macken A., Feeney E., Kenny G., McCann K., Kelly N., Blair M., McCann R., Kenny C., O'Brion C., Waqas S., Savinelli S., Doran P., Bracken T., Varghese P., Lambert J.S., Cotter A., Muldoon E., Sheehan G., McGinty T., Lambert J., Green S., Leamy K., de Barra E., McConkey S., Kelly C., Horgan M., Sadlier C., Yousif O., O'Donnell J., Fitzgerald M., Petty-Saphon N., Cuddihy J., Fiore S., Fabiani C., Benedetti E., Di Mario G., Facchini M., Puzelli S., Calzoletti L., Fontana S., Venturi G., Fortuna C., Marsili G., Amendola A., Stuppia L., Savini G., Picerno A., Lopizzo T., Dell'Edera D., Minchella P., Greco F., Mauro M.V., Viglietto G., Atripaldi L., Limone A., D'Agaro P., Licastro D., Marcello A., Capobianchi M.R., Icardi G., Bruzzone B., Lillo F., Orsi A., Pariani E., Baldanti F., Gismondo M.R., Maggi F., Caruso A., Ceriotti F., Boniotti B., Bagnarelli P., Garofalo S., Scutella M., Pagani E., Collini L., Ghisetti V., Ru G., Chironna M., Parisi A., Rubino S., Serra C., Piras G., Coghe F., Vitale F., Tramuto F., Scalia G., Palermo C.I., Mancuso G., Di Gaudio F., Vullo S., Reale S., Cusi M.G., Rossolini G.M., Pistello M., Mencacci A., Camilloni B., Severini S., Di Benedetto M., Calogero T., Monne I., Biscaro V., and COVID Study Groups more...
- Subjects
Infecções Respiratórias ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Critical Care ,Epidemiology ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,variants of concern ,Settore MED/42 - Igiene Generale E Applicata ,03 medical and health sciences ,0302 clinical medicine ,Virology ,Internal medicine ,Medicine ,Humans ,Intensive care admission ,030212 general & internal medicine ,COVID-19 ,Europe ,SARS-CoV-2 ,surveillance ,Surveillance ,business.industry ,030503 health policy & services ,Public Health, Environmental and Occupational Health ,Odds ratio ,Confidence interval ,Variants of Concern ,COVID-19, Europe, SARS-CoV-2, surveillance, variants of concern ,0305 other medical science ,business ,Rapid Communication ,Human - Abstract
COVID study groups - PORTUGAL: Portuguese Laboratory Network for the Diagnosis of COVID-19 and Public Health Department of the Health Administrative Regions, Physicians that provided data and samples from suspected cases and SARS-CoV-2 genetic characterization. INSA laboratory team for the diagnosis of SARS-CoV-2. Algarve Biomedical Center and Unilabs. We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8). ECDC internal funds. The ICSC and the AIID Cohort are supported by Science Foundation Ireland under the Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding Call (Grant number: COVID-RRC 20/COV/0103 and COVID-RRC 20/COV/0305). info:eu-repo/semantics/publishedVersion more...
- Published
- 2021
5. Salute e sicurezza sul lavoro nelle sale operatorie ibride: un’analisi ergonomica
- Author
-
Monaco, M. G. L., Carta, A., Spiteri, G., Barooty, A., Conforti, R., Maran, F., Rostello, M., Tamhid, T., Visentin, M., and Porru, S.
- Subjects
sale operatorie ,ibride ,salute e sicurezza - Published
- 2022
6. Riduzione del consumo di sale tra i lavoratori della sanità: efficacia di un intervento di promozione della salute
- Author
-
Spiteri, G., Monaco, M. G. L., Tamhid, T., Taus, F., Torroni, L., Verlato, G., Carta, A., and Porru, S.
- Subjects
sanitari ,promozione salute ,sale - Published
- 2022
7. Serological response after SARS-CoV2 vaccination in healthcare workers: a multicenter study
- Author
-
Visci G, Zunarelli C, Mansour I, Porru S, De Palma G, Duval X, Monaco MGL, Spiteri G, Carta A, Lippi G, Verlato G, Sansone E, Sala E, Lombardo M, Abedini M, Violante F, Boffetta P.
- Published
- 2022
- Full Text
- View/download PDF
8. Incidence and severity of pertussis hospitalisations in infants aged less than 1 year in 37 hospitals of six EU/EEA countries, results of PERTINENT sentinel pilot surveillance system, December 2015 to December 2018
- Author
-
Merdrignac L, Aït El Belghiti F, Pandolfi E, Jané M, Murphy J, Fabiánová K, García Cenoz M, Flem E, Guillot S, Tozzi AE, Carmona G, Habington A, Zavadilová J, Navasués A, Bøås H, Lévy-Brühl D, Ferretti B, Miguel Lanaspa Pérez, O'Sullivan N, Krížová P, Fernandino L, Bekkevold T, Hanslik T, Munoz-Almagro C, Bacci S, Spiteri G, Valenciano M, Moren A, PERTINENT Group, and PERTINENT group more...
- Subjects
pertussis ,active surveillance ,hospital surveillance ,pertussis incidence - Abstract
IntroductionPERTINENT is a pilot active surveillance system of infants hospitalised with pertussis in six European Union/European Economic Area countries (37 hospitals, seven sites).AimThis observational study aimed to estimate annual pertussis incidence per site from 2016 to 2018 and respective trends between 2017 and 2018. Pertussis cases were described, including their severity.MethodsWe developed a generic protocol and laboratory guidelines to harmonise practices across sites. Cases were hospitalised infants testing positive for Bordetella pertussis by PCR or culture. Sites collected demographic, clinical, laboratory data, vaccination status, and risk/protective factors. We estimated sites' annual incidences by dividing case numbers by the catchment populations.ResultsFrom December 2015 to December 2018, we identified 469 cases (247 males; 53%). The median age, birthweight and gestational age were 2.5 months (range: 0-11.6; interquartile range (IQR): 2.5), 3,280 g (range: 700-4,925; IQR: 720) and 39 weeks (range: 25-42; IQR: 2), respectively. Thirty cases (6%) had atypical presentation either with cough or cyanosis only or with absence of pertussis-like symptoms. Of 330 cases with information, 83 (25%) were admitted to intensive care units including five deceased infants too young to be vaccinated. Incidence rate ratios between 2018 and 2017 were 1.43 in Czech Republic (p = 0.468), 0.25 in Catalonia (p = 0.002), 0.71 in France (p = 0.034), 0.14 in Ireland (p = 0.002), 0.63 in Italy (p = 0.053), 0.21 in Navarra (p = 0.148) and zero in Norway.ConclusionsIncidence appeared to decrease between 2017 and 2018 in all but one site. Enhanced surveillance of hospitalised pertussis in Europe is essential to monitor pertussis epidemiology and disease burden. more...
- Published
- 2021
9. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.
- Author
-
Funk, T, Pharris, A, Spiteri, G, Bundle, N, Melidou, A, Carr, M, Gonzalez, G, Garcia-Leon, A, Crispie, F, O'Connor, L, Murphy, N, Mossong, J, Vergison, A, Wienecke-Baldacchino, AK, Abdelrahman, T, Riccardo, F, Stefanelli, P, Di Martino, A, Bella, A, Lo Presti, A, Casaca, P, Moreno, J, Borges, V, Isidro, J, Ferreira, R, Gomes, JP, Dotsenko, L, Suija, H, Epstein, J, Sadikova, O, Sepp, H, Ikonen, N, Savolainen-Kopra, C, Blomqvist, S, Möttönen, T, Helve, O, Gomes-Dias, J, Adlhoch, C, COVID study groups, Funk, T, Pharris, A, Spiteri, G, Bundle, N, Melidou, A, Carr, M, Gonzalez, G, Garcia-Leon, A, Crispie, F, O'Connor, L, Murphy, N, Mossong, J, Vergison, A, Wienecke-Baldacchino, AK, Abdelrahman, T, Riccardo, F, Stefanelli, P, Di Martino, A, Bella, A, Lo Presti, A, Casaca, P, Moreno, J, Borges, V, Isidro, J, Ferreira, R, Gomes, JP, Dotsenko, L, Suija, H, Epstein, J, Sadikova, O, Sepp, H, Ikonen, N, Savolainen-Kopra, C, Blomqvist, S, Möttönen, T, Helve, O, Gomes-Dias, J, Adlhoch, C, and COVID study groups more...
- Abstract
We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8). more...
- Published
- 2021
10. The magnitude and distribution of infectious intestinal disease in Malta: a population-based study
- Author
-
GAUCI, C., GILLES, H., OʼBRIEN, S., MAMO, J., STABILE, I., RUGGERI, F. M., GATT, A., CALLEJA, N., and SPITERI, G.
- Published
- 2007
11. Estimating the burden and cost of infectious intestinal disease in the Maltese community
- Author
-
GAUCI, C., GILLES, H., OʼBRIEN, S., MAMO, J., STABILE, I., RUGGERI, F. M., CALLEJA, N., and SPITERI, G.
- Published
- 2007
12. Population-level antimicrobial consumption is associated with decreased antimicrobial susceptibility in Neisseria gonorrhoeae in 24 European countries : an ecological analysis
- Author
-
Kenyon, Chris, Buyze, Jozefien, Spiteri, G., Cole, M. J., Unemo, Magnus, Kenyon, Chris, Buyze, Jozefien, Spiteri, G., Cole, M. J., and Unemo, Magnus
- Abstract
OBJECTIVES: There are substantial variations in Neisseria gonorrhoeae susceptibility to antimicrobials between different populations, and the reasons for this are largely unexplored. We aimed to assess if the population level consumption of antimicrobials is a contributory factor. METHODS: Using antimicrobial susceptibility data from 24 countries in the European Gonococcal Antimicrobial Surveillance Programme and antimicrobial consumption data from the IQVIA MIDAS database, we built mixed effects linear/logistic regression models with country-level cephalosporin, fluoroquinolone and macrolide consumption (standard doses/1000 population/year) as the explanatory variables (from 2009 to 2015) and 1-year lagged ceftriaxone, cefixime, azithromycin and ciprofloxacin geometric mean minimum inhibitory concentrations (MIC) as the outcome variables (2010 to 2016). RESULTS: Positive correlations were found between the consumption of cephalosporins and geometric mean MIC of ceftriaxone and cefixime (both P's <0.05). Fluoroquinolone consumption was positively associated with the prevalence of resistance to ciprofloxacin (P<0.05). CONCLUSIONS: Differences in population level consumption of particular antimicrobials may contribute to the variations in the level of antimicrobial resistance in N. gonorrhoeae in different settings. Further interventions to reduce misuse and overuse of antimicrobials in high-consumption populations and core-groups are required. more...
- Published
- 2020
- Full Text
- View/download PDF
13. Population-Level Antimicrobial Consumption Is Associated With Decreased Antimicrobial Susceptibility in Neisseria gonorrhoeae in 24 European Countries: An Ecological Analysis
- Author
-
Kenyon, Chris, primary, Buyze, Jozefien, additional, Spiteri, G, additional, Cole, M J, additional, and Unemo, M, additional
- Published
- 2019
- Full Text
- View/download PDF
14. Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project
- Author
-
Gini, R. (Rosa), Dodd, C.N. (Caitlin), Bollaerts, K. (Kaatje), Bartolini, C. (Claudia), Roberto, G. (Giuseppe), Huerta Alvarez, C. (C.), Martín-Merino, E. (E.), Duarte-Salles, T. (Talita), Picelli, G. (Gino), Tramontan, L. (Lara), Danieli, G. (Giorgia), Correa, A. (Ana), McGee, C. (C.), Becker, B.F.H. (Benedikt), Switzer, C. (Charlotte), Gandhi-Banga, S. (S.), Bauwens, J. (Jorgen), Maas, N.A.T. (Nicoline) van der, Spiteri, G. (Gianfranco), Sdona, E. (Emmanouela), Weibel, D.M. (Daniel), Sturkenboom, M. (Miriam), Gini, R. (Rosa), Dodd, C.N. (Caitlin), Bollaerts, K. (Kaatje), Bartolini, C. (Claudia), Roberto, G. (Giuseppe), Huerta Alvarez, C. (C.), Martín-Merino, E. (E.), Duarte-Salles, T. (Talita), Picelli, G. (Gino), Tramontan, L. (Lara), Danieli, G. (Giorgia), Correa, A. (Ana), McGee, C. (C.), Becker, B.F.H. (Benedikt), Switzer, C. (Charlotte), Gandhi-Banga, S. (S.), Bauwens, J. (Jorgen), Maas, N.A.T. (Nicoline) van der, Spiteri, G. (Gianfranco), Sdona, E. (Emmanouela), Weibel, D.M. (Daniel), and Sturkenboom, M. (Miriam) more...
- Abstract
Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines using European healthcare databases. Event misclassification can result in biased estimates. Using different algorithms for identifying cases of Bordetella pertussis (BorPer) infection as a test case, we aimed to describe a strategy to quantify event misclassification, when manual chart review is not feasible. Methods: Four participating databases retrieved data from primary care (PC) setting: BIFAP: (Spain), THIN and RCGP RSC (UK) and PEDIANET (Italy); SIDIAP (Spain) retrieved data from both PC and hospital settings. BorPer algorithms were defined by healthcare setting, data domain (diagnoses, drugs, or laboratory tests) and concept sets (specific or unspecified pertussis). Algorithm- and database-specific BorPer incidence rates (IRs) were estimated in children aged 0–14 years enrolled in 2012 and 2014 and followed up until the end of each calendar year and compared with IRs of confirmed pertussis from the ECDC surveillance system (TESSy). Novel formulas were used to approximate validity indices, based on a small set of assumptions. They were applied to approximately estimate positive predictive value (PPV) and sensitivity in SIDIAP. Results: The number of cases and the estimated BorPer IRs per 100,000 person-years in PC, using data representing 3,173,268 person-years, were 0 (IR = 0.0), 21 (IR = 4.3), 21 (IR = 5.1), 79 (IR = 5.7), and 2 (IR = 2.3) in BIFAP, SIDIAP, THIN, RCGP RSC and PEDIANET respectively. The IRs for combined specific/unspecified pertussis were higher than TESSy, suggesting that some false positives had been included. In SIDIAP the estimated IR was 45.0 when discharge diagnoses were included. The sensitivity and PPV of combined PC specific and unspecific diagnoses for BorPer cases in SIDIAP were approximately 85% and 72%, respecti more...
- Published
- 2019
- Full Text
- View/download PDF
15. Patologie non neoplastiche da esposizione lavorativa ad amianto
- Author
-
Porru, S, Feroldi, E, and Spiteri, G
- Subjects
benign pleural abnormalities - occupational exposures - ex exposed ,pleuropatie benigne ,ex esposti ,asbestosi ,asbestosi, pleuropatie benigne, esposizione occupazionale, ex esposti ,esposizione occupazionale - Published
- 2018
16. Travel-associated gonorrhoea in four Nordic countries, 2008 to 2013
- Author
-
Beauté, J, Cowan, S, Hiltunen-Back, E, Kløvstad, Hilde, Velicko, I, and Spiteri, G
- Published
- 2017
17. Trends in HIV surveillance data in the EU/EEA, 2005 to 2014: New HIV diagnoses still increasing in men who have sex with men
- Author
-
Pharris, Anastasia, Quinten, C., Tavoschi, L., Spiteri, G., Amato-Gauci, A. J., Schmid, D., Sasse, A., Beckhoven, D. Van, Varleva, T., Blazic, Tatjana Nemeth, Koliou, M., Hadjihannas, L., Maly, M., Cowan, Susan, Rüütel, K., Liitsola, K., Salminen, M., Cazein, F., Pillonel, J., Lot, F., Gunsenheimer-Bartmeyer, Barbara, Nikolopoulos, Georgios K., Paraskeva, D., Dudas, M., Briem, H., Sigmundsdottir, G., Igoe, D., O’Donnell, K., O’Flanagan, D., Suligoi, B., Konova, S., Erne, S., Caplinskiene, I., Jean-Schmit, C., Melillo, J. M., Melillo, T., Coul, E. Op De, Blystad, H., Rosinska, M., Diniz, A., Mardarescu, Mariana, Truska, P., Klavs, I., Diez, M., Avdicova, Maria, Delpech, Valerie, and Nikolopoulos, Georgios K.[0000-0002-3307-0246] more...
- Subjects
Male ,Delayed Diagnosis ,Epidemiology ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Men who have sex with men ,Risk Factors ,Diagnosis ,Medical diagnosis ,media_common ,human immunodeficiency virus ,Transmission (medicine) ,Human immunodeficiency virus ,AIDS Serodiagnosis ,Homosexuality ,Emigration and Immigration ,Early diagnosis ,Cell count ,Virus diagnosis ,AIDS ,Europe ,Population Surveillance ,Public Health ,Human ,Adult ,medicine.medical_specialty ,Virus transmission ,Cd4+ t lymphocyte ,Acquired immunodeficiency syndrome (AIDS) ,Virology ,medicine ,media_common.cataloged_instance ,Humans ,European Union ,European union ,Homosexuality, Male ,Hiv surveillance ,HIV ,acquired immunodeficiency syndrome ,CD4 Lymphocyte Count ,Public Health, Environmental and Occupational Health ,business.industry ,Prevention ,Environmental and Occupational Health ,medicine.disease ,Immunology ,business ,Demography - Abstract
Human immunodeficiency virus (HIV) transmission remains significant in Europe. Rates of acquired immunodeficiency syndrome (AIDS) have declined, but not in all countries. New HIV diagnoses have increased among native and foreign-born men who have sex with men. Median CD4 + T-cell count at diagnosis has increased, but not in all groups, and late diagnosis remains common. HIV infection and AIDS can be eliminated in Europe with resolute prevention measures, early diagnosis and access to effective treatment. © 2015, European Centre for Disease Prevention and Control (ECDC). All rights reserved. 20 47 more...
- Published
- 2015
18. Second European multi-disciplinary conference of national strategies for Chlamydia trach. and human papillomavirus NSCP conf. in Berlin, 2013 enhanced detection, management and surveillance of sexually transmitted infections in Europe are essential!
- Author
-
Ozolins, D., D' Elios, M. M., Ripa, T., Bailey, R., Timms, P., Spiteri, G., Haar, K., and Unemo, M.
- Subjects
Male ,HPV ,Papillomavirus Infections ,Vaccination ,Sexually Transmitted Diseases ,Chlamydia trachomatis ,Chlamydia Infections ,Congresses as Topic ,Europe ,STI ,surveillance ,diagnostics ,vaccine ,conference ,Female ,Humans ,Mass Screening - Abstract
There is a need for updated guidance on detection, management and surveillance of sexually transmitted infections (STIs). Chlamydia, gonorrhoea and syphilisreporting needs to be mandatory in more European countries to aid collection of data. More widespread Chlamydia screening is needed in many countries as this is the only way to reduce complications. The role of Human Papillomavirus (HPV) screening in a situation where the prevalence of HPV infection has dropped significantly was also discussed in the context of the high cost of screening, the need for a relatively complex infrastructure, particularly in developing countries, and falling vaccination costs. An integrated HPV vaccination and screening policy could be the most appropriate with vaccination at 9-13 years as recommended by WHO and a single HPV screen at 35-39 years, possibly repeated thereafter every 10 years. Female and male HPV vaccination programmes could lead to near elimination of genital warts in both females and males. Surveillance of STIsshould be intensified where needed; additional or better quality data should be collected including reasons for testing, denominator data to estimate positivity rates, diagnostic methods, concurrent STIs, sexual orientation and country of acquisition; more analytical rather than descriptive epidemiology is needed. more...
- Published
- 2013
19. Higher all-cause mortality in children during autumn 2009 compared with the three previous years: pooled results from eight European countries
- Author
-
Mazick, A., Gergonne, B., Wuillaume, F., Danis, K., Apostolos Vantarakis, Uphoff, H., Spiteri, G., Klooster, T., Junker, C., Holmberg, M., and Molbak, K.
- Subjects
Adult ,Adolescent ,Infant, Newborn ,Infant ,Middle Aged ,Europe ,Young Adult ,Cause of Death ,Child, Preschool ,Child Mortality ,Humans ,Registries ,Child ,Aged - Abstract
The paper describes weekly fluctuations of all-cause mortality observed in eight European countries during the period between week 27 and 51, 2009, in comparison with three previous years. Our preliminary data show that the mortality reported during the 2009 influenza pandemic did not reach levels normally seen during seasonal influenza epidemics. However, there was a cumulative excess mortality of 77 cases (1 per 100,000 population) in 5-14-year-olds, and possibly also among 0-4-year-olds. more...
- Published
- 2010
20. Surveillance of Zika virus infection in the EU/EEA, June 2015 to January 2017.
- Author
-
Spiteri, G., Sudre, B., Septfons, A., and Beauté, J.
- Published
- 2017
- Full Text
- View/download PDF
21. Travel-associated gonorrhoea in four Nordic countries, 2008 to 2013.
- Author
-
Beauté, J., Cowan, S., Hiltunen-Back, E., Kløvstad, H., Velicko, I., and Spiteri, G.
- Published
- 2017
- Full Text
- View/download PDF
22. Ten years after Dublin: principal trends in HIV surveillance in the EU/EEA, 2004 to 2013
- Author
-
Pharris, A, primary, Spiteri, G, additional, Noori, T, additional, and Amato-Gauci, A J, additional
- Published
- 2014
- Full Text
- View/download PDF
23. Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe
- Author
-
Cole, M J, primary, Spiteri, G, additional, Chisholm, S A, additional, Hoffmann, S, additional, Ison, C A, additional, Unemo, M, additional, and Van de Laar, M, additional
- Published
- 2014
- Full Text
- View/download PDF
24. Surveillance of human immunodeficiency virus suggests that younger men who have sex with men are at higher risk of infection, European Union, 2003 to 2012
- Author
-
Janiec, J, primary, Haar, K, additional, Spiteri, G, additional, Likatavicius, G, additional, Van de Laar, M, additional, and Amato-Gauci, A J, additional
- Published
- 2013
- Full Text
- View/download PDF
25. P3.136 Epidemic of Lymphogranuloma Venereum (LGV) in Europe
- Author
-
Haar, K, primary, Spiteri, G, additional, Sfetcu, O, additional, and Laar, M van de, additional
- Published
- 2013
- Full Text
- View/download PDF
26. O03.5 Recent Increases in Gonorrhoea in Europe
- Author
-
Spiteri, G, primary, Haar, K, additional, Sfetcu, O, additional, and Laar, M van de, additional
- Published
- 2013
- Full Text
- View/download PDF
27. O03.2 Antimicrobial Resistance of Neisseria Gonorrhoeae in the European Union: Response to the Threat of Multidrug Resistant Gonorrhoea
- Author
-
Spiteri, G, primary, Cole, M, additional, Unemo, M, additional, Hoffmann, S, additional, Ison, C, additional, and Laar, M van de, additional
- Published
- 2013
- Full Text
- View/download PDF
28. S13.3 The Status of HIV Prevention Among MSM: An Overview of the European Response
- Author
-
Sfetcu, O, primary, Noori, T, additional, Spiteri, G, additional, Pharris, A, additional, and Laar, M van de, additional
- Published
- 2013
- Full Text
- View/download PDF
29. P5.008 Performance of antenatal screening for HIV and syphilis in EU/EEA, during 2006–2011: making use of surveillance data
- Author
-
Sfetcu, O, primary, Cleeve, A, additional, Likatavicius, G, additional, Spiteri, G, additional, and Laar, M van de, additional
- Published
- 2013
- Full Text
- View/download PDF
30. O03.1 Risk Factors For Antimicrobial ResistantNeisseria Gonorrhoeaein Europe: Abstract O03.1 Table 1
- Author
-
Cole, M J, primary, Spiteri, G, additional, Town, K, additional, Unemo, M, additional, Hoffmann, S, additional, Laar, M van de, additional, and Ison, C, additional
- Published
- 2013
- Full Text
- View/download PDF
31. P3.241 Epidemiology of Sexually Transmitted Infections in Europe 1990–2011
- Author
-
Spiteri, G, primary and Laar, M van de, additional
- Published
- 2013
- Full Text
- View/download PDF
32. Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe
- Author
-
Van de Laar, M, primary and Spiteri, G, additional
- Published
- 2012
- Full Text
- View/download PDF
33. A cluster of rubella in Malta, December 2007 - January 2008
- Author
-
Spiteri, G, primary, Fenech Magrin, A-M, additional, and Muscat, M, additional
- Published
- 2008
- Full Text
- View/download PDF
34. Trends in HIV surveillance data in the EU/EEA, 2005 to 2014: new HIV diagnoses still increasing in men who have sex with men.
- Author
-
Pharris, A., Quinten, C., Tavoschi, L., Spiteri, G., and Amato-Gauci, AJ
- Published
- 2015
- Full Text
- View/download PDF
35. Second European Multi-Disciplinary Conference of National Strategies for Chlamydia Trachomatisand Human Papillomavirus (NSCP Conference) in Berlin, 2013 — Enhanced Detection, Management and Surveillance of Sexually Transmitted Infections in Europe are Essential!
- Author
-
Ozolins, D., D'Elios, M.M., Ripa, T., Bailey, R., Timms, P., Spiteri, G., Haar, K., and Unemo, M.
- Abstract
There is a need for updated guidance on detection, management and surveillance of sexually transmitted infections (STIs). Chlamydia, gonorrhoea and syphilis reporting needs to be mandatory in more European countries to aid collection of data. More widespread Chlamydia screening is needed in many countries as this is the only way to reduce complications. The role of Human Papillomavirus (HPV) screening in a situation where the prevalence of HPV infection has dropped significantly was also discussed in the context of the high cost of screening, the need for a relatively complex infrastructure, particularly in developing countries, and falling vaccination costs. An integrated HPV vaccination and screening policy could be the most appropriate with vaccination at 9–13 years as recommended by WHO and a single HPV screen at 35–39 years, possibly repeated thereafter every 10 years. Female and male HPV vaccination programmes could lead to near elimination of genital warts in both females and males. Surveillance of STIs should be intensified where needed; additional or better quality data should be collected including reasons for testing, denominator data to estimate positivity rates, diagnostic methods, concurrent STIs, sexual orientation and country of acquisition; more analytical rather than descriptive epidemiology is needed. more...
- Published
- 2013
- Full Text
- View/download PDF
36. WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2 mg/L) Neisseria gonorrhoeae isolates in Europe from 2009 to 2014
- Author
-
Jacobsson S, Golparian D, Cole M, Spiteri G, Martin I, Bergheim T, Maria José Borrego, Crowley B, Crucitti T, Ap, Dam, Hoffmann S, Jeverica S, Kohl P, Mlynarczyk-Bonikowska B, Pakarna G, Stary A, Stefanelli P, Pavlik P, Tzelepi E, and Abad R more...
37. SARS-CoV-2 Breakthrough Infections: Incidence and Risk Factors in a Large European Multicentric Cohort of Health Workers
- Author
-
Stefano Porru, Maria Grazia Lourdes Monaco, Gianluca Spiteri, Angela Carta, Maria Diletta Pezzani, Giuseppe Lippi, Davide Gibellini, Evelina Tacconelli, Ilaria Dalla Vecchia, Emma Sala, Emanuele Sansone, Giuseppe De Palma, Carlo Bonfanti, Massimo Lombardo, Luigina Terlenghi, Enrico Pira, Ihab Mansour, Maurizio Coggiola, Catalina Ciocan, Alessandro Godono, Adonina Tardon, Marta-Maria Rodriguez-Suarez, Guillermo Fernandez-Tardon, Francisco-Jose Jimeno-Demuth, Rafael-Vicente Castro-Delgado, Tania Iglesias Cabo, Maria Luisa Scapellato, Filippo Liviero, Angelo Moretto, Paola Mason, Sofia Pavanello, Anna Volpin, Luigi Vimercati, Silvio Tafuri, Luigi De Maria, Stefania Sponselli, Pasquale Stefanizzi, Antonio Caputi, Fabriziomaria Gobba, Alberto Modenese, Loretta Casolari, Denise Garavini, Cristiana D’Elia, Stefania Mariani, Francesca Larese Filon, Luca Cegolon, Corrado Negro, Federico Ronchese, Francesca Rui, Paola De Michieli, Nicola Murgia, Marco Dell’Omo, Giacomo Muzi, Tiziana Fiordi, Angela Gambelunghe, Ilenia Folletti, Dana Mates, Violeta Claudia Calota, Andra Neamtu, Ovidiu Perseca, Catalin Alexandru Staicu, Angelica Voinoiu, Eleonóra Fabiánová, Jana Bérešová, Zora Kľocová Adamčáková, Roman Nedela, Anna Lesňáková, Jana Holčíková, Paolo Boffetta, Mahsa Abedini, Giorgia Ditano, Shuffield Seyram Asafo, Giovanni Visci, Francesco Saverio Violante, Carlotta Zunarelli, Giuseppe Verlato, Porru, S, Monaco, Mgl, Spiteri, G, Carta, A, Pezzani, Md, Lippi, G, Gibellini, D, Tacconelli, E, Dalla Vecchia, I, Sala, E, Sansone, E, De Palma, G, Bonfanti, C, Lombardo, M, Terlenghi, L, Pira, E, Mansour, I, Coggiola, M, Ciocan, C, Godono, A, Tardon, A, Rodriguez-Suarez, Mm, Fernandez-Tardon, G, Jimeno-Demuth, Fj, Castro-Delgado, Rv, Iglesias Cabo, T, Scapellato, Ml, Liviero, F, Moretto, A, Mason, P, Pavanello, S, Volpin, A, Vimercati, L, Tafuri, S, De Maria, L, Sponselli, S, Stefanizzi, P, Caputi, A, Gobba, F, Modenese, A, Casolari, L, Garavini, D, D'Elia, C, Mariani, S, Filon, Fl, Cegolon, L, Negro, C, Ronchese, F, Rui, F, De Michieli, P, Murgia, N, Dell'Omo, M, Muzi, G, Fiordi, T, Gambelunghe, A, Folletti, I, Mates, D, Calota, Vc, Neamtu, A, Perseca, O, Staicu, Ca, Voinoiu, A, Fabiánová, E, Bérešová, J, Adamčáková, Zk, Nedela, R, Lesňáková, A, Holčíková, J, Boffetta, P, Abedini, M, Ditano, G, Asafo, S, Visci, G, Violante, F, Zunarelli, C, Verlato, G, Porru S., Monaco M.G.L., Spiteri G., Carta A., Pezzani M.D., Lippi G., Gibellini D., Tacconelli E., Dalla Vecchia I., Sala E., Sansone E., De Palma G., Bonfanti C., Lombardo M., Terlenghi L., Pira E., Mansour I., Coggiola M., Ciocan C., Godono A., Tardon A., Rodriguez-Suarez M.-M., Fernandez-Tardon G., Jimeno-Demuth F.-J., Castro-Delgado R.-V., Iglesias Cabo T., Scapellato M.L., Liviero F., Moretto A., Mason P., Pavanello S., Volpin A., Vimercati L., Tafuri S., De Maria L., Sponselli S., Stefanizzi P., Caputi A., Gobba F., Modenese A., Casolari L., Garavini D., D'Elia C., Mariani S., Filon F.L., Cegolon L., Negro C., Ronchese F., Rui F., De Michieli P., Murgia N., Dell'Omo M., Muzi G., Fiordi T., Gambelunghe A., Folletti I., Mates D., Calota V.C., Neamtu A., Perseca O., Staicu C.A., Voinoiu A., Fabianova E., Beresova J., Adamcakova Z.K., Nedela R., Lesnakova A., Holcikova J., Boffetta P., Abedini M., Ditano G., Asafo S.S., Visci G., Violante F.S., Zunarelli C., and Verlato G. more...
- Subjects
Pharmacology ,health worker ,COVID-19 ,SARS-CoV-2 vaccination ,breakthrough infections ,health workers ,occupational and socio-demographic determinants ,Immunology ,breakthrough infection ,Infectious Diseases ,occupational and socio-demographic determinant ,Drug Discovery ,Pharmacology (medical) - Abstract
European Commission, H2020 [101016167]; Regional Health Authority (Azienda Zero), Veneto Region, Italy; Health Research Institute of Asturias (ISPA), Spain, Porru S, Monaco MGL, Spiteri G, Carta A, Pezzani MD, Lippi G, Gibellini D, Tacconelli E, Dalla Vecchia I, Sala E, Sansone E, De Palma G, Bonfanti C, Lombardo M, Terlenghi L, Pira E, Mansour I, Coggiola M, Ciocan C, Godono A, Tardon A, Rodriguez-Suarez MM, Fernandez-Tardon G, Jimeno-Demuth FJ, Castro-Delgado RV, Iglesias Cabo T, Scapellato ML, Liviero F, Moretto A, Mason P, Pavanello S, Volpin A, Vimercati L, Tafuri S, De Maria L, Sponselli S, Stefanizzi P, Caputi A, Gobba F, Modenese A, Casolari L, Garavini D, D'Elia C, Mariani S, Filon FL, Cegolon L, Negro C, Ronchese F, Rui F, De Michieli P, Murgia N, Dell'Omo M, Muzi G, Fiordi T, Gambelunghe A, Folletti I, Mates D, Calota VC, Neamtu A, Perseca O, Staicu CA, Voinoiu A, Fabiánová E, Bérešová J, Adamčáková ZK, Nedela R, Lesňáková A, Holčíková J, Boffetta P, Abedini M, Ditano G, Asafo SS, Visci G, Violante FS, Zunarelli C, Verlato G more...
- Published
- 2022
38. Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers - ORCHESTRA project
- Author
-
Collatuzzo, Giulia, Visci, Giovanni, Violante, Francesco S, Porru, Stefano, Spiteri, Gianluca, Monaco, Maria Grazia Lourdes, Larese Fillon, Francesca, Negro, Corrado, Janke, Christian, Castelletti, Noemi, De Palma, Giuseppe, Sansone, Emanuele, Mates, Dana, Teodorescu, Silvia, Fabiánová, Eleonóra, Bérešová, Jana, Vimercati, Luigi, Tafuri, Silvio, Abedini, Mahsa, Ditano, Giorgia, Asafo, Shuffield S, Boffetta, Paolo, Zunarelli, Carlotta, Bonfiglioli, Roberta, Carta, Angela, Verlato, Giuseppe, Lippi, Giuseppe, Gibellini, Davide, Pezzani, Maria Diletta, Torroni, Lorena, Hoelscher, Michael, Wieser, Andreas, Reinkemeyer, Christina, Plank, Michael, Noreña, Ivan, Rubio-Acero, Raquel, Winter, Simon, Leustean, Mihaela, Perseca, Ovidiu, Ipate, Madalina, Agripina, Rascu, Strhársky, Jozef, Hellebrandt, Petra, Križanová, Daniela, Mrázová, Marianna, De Maria, Luigi, Sponselli, Stefania, Stefanizzi, Pasquale, Caputi, Antonio, Collatuzzo G., Visci G., Violante F.S., Porru S., Spiteri G., Monaco M.G.L., Larese Fillon F., Negro C., Janke C., Castelletti N., De Palma G., Sansone E., Mates D., Teodorescu S., Fabianova E., Beresova J., Vimercati L., Tafuri S., Abedini M., Ditano G., Asafo S.S., and Boffetta P. more...
- Subjects
COVID-19 Vaccines ,vaccine, COVID – 19, serology, health care workers (HCW), immune response ,Health Personnel ,Immunology ,COVID – 19 ,Vaccination ,health care workers (HCW) ,Immunity ,immune response ,serology ,vaccine ,Infant ,COVID-19 ,Antibodies, Viral ,Antibodies ,Immunoglobulin G ,Immunology and Allergy ,Humans ,Female ,Viral ,Human - Abstract
BackgroundThe duration of immune response to COVID-19 vaccination is of major interest. Our aim was to analyze the determinants of anti-SARS-CoV-2 IgG titer at 6 months after 2-dose vaccination in an international cohort of vaccinated healthcare workers (HCWs).MethodsWe analyzed data on levels of anti-SARS-CoV-2 Spike antibodies and sociodemographic and clinical characteristics of 6,327 vaccinated HCWs from 8 centers from Germany, Italy, Romania and Slovakia. Time between 1st dose and serology ranged 150-210 days. Serological levels were log-transformed to account for the skewness of the distribution and normalized by dividing them by center-specific standard errors, obtaining standardized values. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of 1 standard deviation of log antibody level and corresponding 95% confidence interval (CI), and finally combined them in random-effects meta-analyses.ResultsA 6-month serological response was detected in 99.6% of HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection (RR 2.26, 95%CI 1.73-2.95) and two vaccine doses (RR 1.50, 95%CI 1.22-1.84) predicted higher IgG titer, contrary to interval since last dose (RR for 10-day increase 0.94, 95%CI 0.91-0.97) and age (RR for 10-year increase 0.87, 95%CI 0.83-0.92). M-RNA-based vaccines (pConclusionsFemale gender, young age, past infection, two vaccine doses, and m-RNA and heterologous vaccination predicted higher antibody level at 6 months. These results corroborate previous findings and offer valuable data for comparison with trends observed with longer follow-ups. more...
- Published
- 2022
39. Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers-ORCHESTRA Project
- Author
-
Giulia Collatuzzo, Vittorio Lodi, Daniela Feola, Giuseppe De Palma, Emanuele Sansone, Emma Sala, Christian Janke, Noemi Castelletti, Stefano Porru, Gianluca Spiteri, Maria Grazia Lourdes Monaco, Francesca Larese Filon, Corrado Negro, Luca Cegolon, Jana Beresova, Eleonora Fabianova, Lucia A. Carrasco-Ribelles, Pere Toràn-Monserrat, Marta Maria Rodriguez-Suarez, Guillermo Fernandez-Tardon, Shuffield S. Asafo, Giorgia Ditano, Mahsa Abedini, Paolo Boffetta, Collatuzzo, G, Lodi, V, Feola, D, De Palma, G, Sansone, E, Sala, E, Janke, C, Castelletti, N, Porru, S, Spiteri, G, Monaco, Mgl, Larese Filon, F, Negro, C, Cegolon, L, Beresova, J, Fabianova, E, Carrasco-Ribelles, La, Toràn-Monserrat, P, Rodriguez-Suarez, Mm, Fernandez-Tardon, G, Asafo, S, Ditano, G, Abedini, M, and Boffetta, P. more...
- Subjects
Infectious Diseases ,temporal trends ,antibody level ,temporal trend ,Virology ,COVID-19 ,vaccine ,serology ,immunization - Abstract
This project has received funding from the EU Horizon 2020 research and innovation program under the ORCHESTRA project Grant Agreement No. 101016167. The cohort from Verona is funded by the Regional Health Authority (Azienda Zero), Veneto Region, Italy., Collatuzzo G., Lodi V., Feola D., De Palma G., Sansone E., Sala E., Janke C., Castelletti N., Porru S., Spiteri G., Monaco M.G.L., Larese Filon F., Negro C., Cegolon L., Beresova J., Fabianova E., Carrasco-Ribelles L.A., Toràn-Monserrat P., Rodriguez-Suarez M.M., Fernandez-Tardon G., Asafo S.S., Ditano G., Abedini M., Boffetta P. more...
- Published
- 2022
40. Gastritis and gastroesophageal reflux disease are strongly associated with non-allergic nasal disorders
- Author
-
Gianluca Spiteri, Eliana Finocchio, Salvatore Battaglia, Marcello Ferrari, Francesca Sanna, Nicola Murgia, Giuseppe Verlato, Leonardo Antonicelli, Pierpaolo Marchetti, Pietro Pirina, Angelo Corsico, Mario Olivieri, Francesca Locatelli, Roberta Vesentini, Roberto Bono, Finocchio E., Locatelli F., Sanna F., Vesentini R., Marchetti P., Spiteri G., Antonicelli L., Battaglia S., Bono R., Corsico A.G., Ferrari M., Murgia N., Pirina P., Olivieri M., and Verlato G. more...
- Subjects
Male ,Non-allergic rhinitis ,Gastroesophageal reflux disease ,Gastroenterology ,Allergic rhinitis ,0302 clinical medicine ,Prevalence ,Non-allergic rhiniti ,030223 otorhinolaryngology ,Sinusitis ,Rhinitis ,Aged, 80 and over ,education.field_of_study ,Middle Aged ,Gastritit ,Italy ,Gastritis ,Gastroesophageal Reflux ,Female ,Public Health ,medicine.symptom ,Research Article ,Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Population ,Gastritits ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,NO ,Hiatal hernia ,Gastritits, Gastroesophageal refux disease, Allergic rhinitis, Non-allergic rhinitis, Sinusitis ,Young Adult ,03 medical and health sciences ,Internal medicine ,Allergic rhiniti ,medicine ,Humans ,Gastroesophageal refux disease ,education ,Aged ,lcsh:RC705-779 ,business.industry ,lcsh:Diseases of the respiratory system ,medicine.disease ,Rhinitis, Allergic ,Sinusiti ,digestive system diseases ,030228 respiratory system ,Relative risk ,Chronic Disease ,GERD ,Sinusitis, Public Health ,business ,Esophagitis - Abstract
BackgroundGastroesophageal reflux disease (GERD) has been reported to be significantly associated with chronic rhinosinusitis, but the strength of the association is still debated.AimsTo evaluate the strength of the association between gastritis/GERD and non-allergic rhinitis (NAR)/allergic rhinitis (AR)/sinusitis.MethodsWe investigated 2887 subjects aged 20–84 years, who underwent a clinical visit in seven Italian centres (Ancona, Palermo, Pavia, Terni, Sassari, Torino, Verona) within the study on Gene Environment Interactions in Respiratory Diseases, a population-based multicase-control study between 2008 and 2014. Subjects were asked if they had doctor-diagnosed “gastritis or stomach ulcer (confirmed by gastroscopy)” or “gastroesophageal reflux disease, hiatal hernia or esophagitis”. The association between NAR/AR/sinusitis and either gastritis or GERD was evaluated through relative risk ratios (RRR) by multinomial logistic regression.ResultsThe prevalence of gastritis/GERD increased from subjects without nasal disturbances (22.8% = 323/1414) to subjects with AR (25.8% = 152/590) and further to subjects with NAR (36.7% = 69/188) or sinusitis (39.9% = 276/691). When adjusting for centre, sex, age, education level, BMI, smoking habits and alcohol intake, the combination of gastritis and GERD was associated with a four-fold increase in the risk of NAR (RRR = 3.80, 95% CI 2.56–5.62) and sinusitis (RRR = 3.70, 2.62–5.23) with respect to controls, and with a much smaller increase in the risk of AR (RRR = 1.79, 1.37–2.35)..ConclusionThe study confirmed the association between gastritis/GERD and nasal disturbances, which is stronger for NAR and sinusitis than for AR. more...
- Published
- 2021
41. Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project.
- Author
-
Spiteri G, D'Agostini M, Abedini M, Ditano G, Collatuzzo G, Boffetta P, Vimercati L, Sansone E, De Palma G, Modenese A, Gobba F, Liviero F, Moretto A, dell'Omo M, Fiordi T, Larese Filon F, Mauro M, Violán C, Mates D, Oravec Bérešová J, Monaco MGL, Carta A, Verlato G, and Porru S more...
- Subjects
- Humans, Europe epidemiology, Female, Adult, Male, Middle Aged, Immunization, Secondary, Spike Glycoprotein, Coronavirus immunology, Breakthrough Infections, COVID-19 prevention & control, COVID-19 immunology, Health Personnel statistics & numerical data, SARS-CoV-2 immunology, Immunoglobulin G blood, Antibodies, Viral blood, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage
- Abstract
Purpose: Anti SARS-CoV-2 vaccination initially showed high effectiveness in preventing COVID-19. However, after the surge of variants of concern, the effectiveness dropped. Several studies investigated if this was related to the decrease of the humoral response over time; however, this issue is still unclear. The aim of this study was to understand whether SARS-CoV-2 anti-S IgG levels can be used to predict breakthrough infection risk and define the timing for further booster doses administration., Method: Within the framework of the ORCHESTRA Project, over 20,000 health workers from 11 European centers were enrolled since December 2020. We performed two Cox proportional hazards survival analyses regarding pre-Omicron (from January to July 2021) and Omicron (December 2021-May 2022) periods. The serological response was classified as high (above the 75th percentile), medium (25th-75th), or low (< 25th)., Results: Seventy-four (0.33%) and 2122 (20%) health workers were infected during the first and second periods, respectively. Both Cox analyses showed that having high anti-S titer was linked to a significantly lower risk of infection as compared to having medium serological response [HR of high vs medium anti-S titer = 0.27 (95% CI 0.11-0.66) during the first phase, HR = 0.76 (95% CI 0.62-0.93) during the second phase]., Conclusion: Vaccine effectiveness wanes significantly after new variants surge, making anti-S titer unsuitable to predict optimal timing for further booster dose administration. Studies on other immunological indicators, such as cellular immunity, are therefore needed to better understand the mechanisms and duration of protection against breakthrough infection risk., (© 2024. The Author(s).) more...
- Published
- 2024
- Full Text
- View/download PDF
42. Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV.
- Author
-
Gupta A, Righi E, Konnova A, Sciammarella C, Spiteri G, Van Averbeke V, Berkell M, Hotterbeekx A, Sartor A, Mirandola M, Malhotra-Kumar S, Azzini AM, Pezzani D, Monaco MGL, Vanham G, Porru S, Tacconelli E, and Kumar-Singh S more...
- Subjects
- Humans, Male, Middle Aged, Female, Adult, CD4 Lymphocyte Count, Vaccination, Immunoglobulin G blood, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, CD4-Positive T-Lymphocytes immunology, HIV Infections immunology, HIV Infections drug therapy, Interleukin-2, COVID-19 immunology, COVID-19 prevention & control, SARS-CoV-2 immunology, Antibodies, Viral blood, Lymphocyte Activation, COVID-19 Vaccines immunology
- Abstract
People living with HIV (PLWH) despite having an appreciable depletion of CD4
+ T-cells show a good severe acute respiratory syndrome coronavirus 2 vaccination response. The underlying mechanism(s) are currently not understood. We studied serological and polyfunctional T-cell responses in PLWH receiving anti-retroviral therapy stratified on CD4+ counts as PLWH-high (CD4 ≥ 500 cells/mm3 ) and PLWH-low (<500 cells/mm3 ). Responses were assessed longitudinally before the first vaccination (T0), 1-month after the first dose (T1), 3-months (T2), and 6-months (T3) after the second dose. Expectedly, both PLWH-high and -low groups developed similar serological responses after T2, which were also non-significantly different from age and vaccination-matched HIV-negative controls at T3. The immunoglobulin G titers were also protective showing a good correlation with angiotensin-converting enzyme 2-neutralizations (R = 0.628, p = 0.005). While surface and intracellular activation analysis showed no significant difference at T3 between PLWH and controls in activated CD4+ CD154+ and CD4+ memory T-cells, spike-specific CD4+ polyfunctional cytokine expression analysis showed that PLWH preferentially express interleukin (IL)-2 (p < 0.001) and controls, interferon-γ (p = 0.017). CD4+ T-cell counts negatively correlated with IL-2-expressing CD4+ T-cells including CD4+ memory T-cells (Spearman ρ: -0.85 and -0.80, respectively; p < 0.001). Our results suggest that the durable serological and CD4+ T-cell responses developing in vaccinated PLWH are associated with IL-2-mediated CD4+ T-cell activation that likely compensates for CD4+ T-cell depletion in PLWH., (© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.) more...- Published
- 2024
- Full Text
- View/download PDF
43. Focus, vigilance, resilience: towards stronger infectious disease surveillance, threat detection and response in the EU/EEA.
- Author
-
Zucs P, Beauté J, Palm D, and Spiteri G
- Subjects
- Humans, Population Surveillance, Europe epidemiology, Disease Outbreaks prevention & control, Sentinel Surveillance, Communicable Disease Control methods, Public Health Surveillance methods, European Union, Communicable Diseases epidemiology, Communicable Diseases diagnosis, Public Health
- Abstract
This perspective summarises and explains the long-term surveillance framework 2021-2027 for infectious diseases in the European Union/European Economic Area (EU/EEA) published in April 2023. It shows how shortcomings in the areas of public health focus, vigilance and resilience will be addressed through specific strategies in the coming years and how these strategies will lead to stronger surveillance systems for early detection and monitoring of public health threats as well as informing their effective prevention and control. A sharper public health focus is expected from a more targeted list of notifiable diseases, strictly public-health-objective-driven surveillance standards, and consequently, leaner surveillance systems. Vigilance should improve through mandatory event reporting, more automated epidemic intelligence processing and increased use of genomic surveillance. Finally, EU/EEA surveillance systems should become more resilient by modernising the underlying information technology infrastructure, expanding the influenza sentinel surveillance system to other respiratory viruses for better pandemic preparedness, and increasingly exploiting potentially more robust alternative data sources, such as electronic health records and wastewater surveillance. Continued close collaboration across EU/EEA countries will be key to ensuring the full implementation of this surveillance framework and more effective disease prevention and control. more...
- Published
- 2024
- Full Text
- View/download PDF
44. SARS-CoV-2 Positivity in Foreign-Born Adults: A Retrospective Study in Verona, Northeast Italy.
- Author
-
Lotti V, Spiteri G, Caliskan G, Monaco MGL, Gibellini D, Verlato G, and Porru S
- Abstract
We compared SARS-CoV-2 positivity between the foreign-born adult working population and Italians living in the Verona area to investigate whether being a foreign-born adult could confer an increased risk of infection or lead to a diagnostic delay. The present study included 105,774 subjects, aged 18-65 years, tested for SARS-CoV-2 by nasopharyngeal swabs and analyzed at the University Hospital of Verona between January 2020 and September 2022. A logistic regression model was used, controlling for gender, age, time of sampling, and source of referral. A higher proportion of SARS-CoV-2 positivity in Italian (30.09%) than in foreign-born (25.61%) adults was reported, with a higher proportion of SARS-CoV-2 positivity in men than women in both cohorts analyzed. The difference in swab positivity among Italian and foreign-born adults was the highest in people aged 18-29 years (31.5% vs. 23.3%) and tended to disappear thereafter. Swab positivity became comparable between Italian and foreign-born adults during the vaccination campaign. Multivariable analysis confirmed the lower risk of swab positivity among foreign-born adults (OR = 0.85, 95% CI 0.82-0.89). In the Verona area, foreign-born adults showed a lower rate of SARS-CoV-2 positivity than the native population, likely because of underdiagnosis. Hence, public health should increase attention toward these particularly vulnerable populations., Competing Interests: The authors declare no conflicts of interest. more...
- Published
- 2024
- Full Text
- View/download PDF
45. Risk of obstructive sleep apnea among health workers: results of a screening in a large Italian University Hospital.
- Author
-
Spiteri G, Monaco MGL, Carta A, Taus F, Torroni L, Verlato G, and Porru S
- Subjects
- Humans, Male, Quality of Life, Polysomnography, Surveys and Questionnaires, Hospitals, Italy epidemiology, Mass Screening methods, Sleep Apnea, Obstructive diagnosis, Sleep Apnea, Obstructive epidemiology
- Abstract
Purpose: Obstructive sleep apnea (OSA) is a common respiratory sleep disorder, related to increased mortality, poor quality of life, and higher risk of work accidents and injuries. Studies on the risk of OSA (rOSA) among health workers (HW) are scant. The aims of this study were to investigate this issue in a large University Hospital and to assess the effectiveness of a screening program., Methods: The STOP-BANG questionnaire (SBQ) was sent via e-mail to the 5031 HW employed at the University Hospital of Verona. HW who completed the SBQ were classified at low, moderate, and high rOSA. HW at high rOSA were invited to undergo nocturnal polygraphy. The determinants of rOSA were studied by non-parametric Kruskal-Wallis test, Pearson's chi-squared, and multinomial logistic model., Results: Of 5031 HW, 1564 (31.1%) completed the online questionnaire. Responders with low, moderate, and high rOSA were 72.7%, 13.7%, and 13.6%. Male gender, older age, and higher body mass index (BMI) were significant predictors of high rOSA, as expected. Physicians had the lowest probability of being in the high-risk category. Polygraphy was performed in 64 subjects. The positive predictive value of the self-administered SBQ was 68.8% (95%C.I. 55.9-79.8%) but raised to 96.9% (95%C.I. 89.2-99.6%) when re-administered by medical staff., Conclusion: SBQ showed its effectiveness as a screening tool in detecting undiagnosed OSA in HW. Systematic screening for OSA in work settings could allow early diagnosis and treatment, reducing short- and long-term health effects of OSA., (© 2023. The Author(s).) more...
- Published
- 2024
- Full Text
- View/download PDF
46. A Multi-Center Study Investigating Long COVID-19 in Healthcare Workers from North-Eastern Italy: Prevalence, Risk Factors and the Impact of Pre-Existing Humoral Immunity-ORCHESTRA Project.
- Author
-
Cegolon L, Mauro M, Sansone D, Tassinari A, Gobba FM, Modenese A, Casolari L, Liviero F, Pavanello S, Scapellato ML, Taus F, Carta A, Spiteri G, Monaco MGL, Porru S, and Larese Filon F
- Abstract
Introduction: The impact of long-COVID-19 syndrome is rather variable, since it is influenced by several residual confounders. This study aimed to investigate the prevalence of long COVID-19 in healthcare workers (HCWs) from four university hospitals in north-eastern Italy: Trieste, Padua, Verona, and Modena-Reggio Emilia. Methods: During the period June 2022-August 2022, HCWs were surveyed for past COVID-19 infections, medical history, and any acute as well as post-COVID-19 symptoms. The prevalence of long COVID-19 was estimated at 30-60 days or 61+ days since first negative swab following first and second COVID-19 episode. Furthermore, the risk of long COVID-19 was investigated by multivariable logistic regression. Results were expressed as the adjusted odds ratio (aOR) with a 95% confidence interval (95%CI). Results: 5432 HCWs returned a usable questionnaire: 2401 were infected with SARS-CoV-2 at least once, 230 were infected at least twice, and 8 were infected three times. The prevalence of long COVID-19 after a primary COVID-19 infection was 24.0% at 30-60 days versus 16.3% at 61+ days, and 10.5% against 5.5% after the second SARS-CoV-2 event. The most frequent symptoms after a first COVID-19 event were asthenia (30.3%), followed by myalgia (13.7%), cough (12.4%), dyspnea (10.2%), concentration deficit (8.1%), headache (7.3%), and anosmia (6.5%), in decreasing order of prevalence. The risk of long COVID-19 at 30-60 days was significantly higher in HCWs hospitalized for COVID-19 (aOR = 3.34; 95%CI: 1.62; 6.89), those infected with SARS-CoV-2 during the early pandemic waves-namely the Wuhan (aOR = 2.16; 95%CI: 1.14; 4.09) or Alpha (aOR= 2.05; 95%CI: 1.25; 3.38) transmission periods-and progressively increasing with viral shedding time (VST), especially 15+ days (aOR = 3.20; 95%CI: 2.07; 4.94). Further determinants of long COVID-19 at 30-60 days since primary COVID-19 event were female sex (aOR = 1.91; 95%CI: 1.30; 2.80), age >40 years, abnormal BMI, or administrative services (reference category). In contrast, HCWs vaccinated with two doses before their primary infection (aOR = 0.57; 95%CI: 0.34; 0.94), undergraduate students, or postgraduate medical trainees were less likely to experience long COVID-19 at 30-60 days. Apart from pandemic waves, the main determinants of long COVID-19 at 30-60 days were confirmed at 61+ days. Conclusions: The risk of long COVID-19 following primary infection increased with the severity of acute disease and VST, especially during the initial pandemic waves, when more virulent viral strains were circulating, and susceptibility to SARS-CoV-2 was higher since most HCWs had not been infected yet, COVID-19 vaccines were still not available, and/or vaccination coverage was still building up. The risk of long COVID-19 therefore decreased inversely with humoral immunity at the individual level. Nevertheless, the prevalence of long COVID-19 was remarkably lower after SARS-CoV-2 reinfections regardless of vaccination status, suggesting that hybrid humoral immunity did not increase protection against the syndrome compared to immunity mounted by either natural infection or vaccination separately. Since the risk of long COVID-19 is currently low with Omicron and patients who developed the syndrome following SARS-CoV-2 infection in the early pandemic waves tend to return to a state of full health with time, a cost-effective approach to screen post-COVID-19 symptoms during the Omicron time could be restricted to vulnerable individuals developing severe disease and/or with prolonged VST. more...
- Published
- 2023
- Full Text
- View/download PDF
47. [The role of exposure to airborne pollutants in the workplace on the prevalence and severity of chronic respiratory disease in Italy].
- Author
-
Locatelli F, Murgia N, Baldacci S, Battaglia S, Bilò MB, Calciano L, Squillacioti G, Corsico A, Gariazzo C, Marchetti P, Massari S, Pirina P, Spiteri G, Torroni L, Viegi G, Verlato G, Marcon A, and Maio S more...
- Subjects
- Humans, Prevalence, Risk Factors, Italy epidemiology, Workplace, Gases, Bronchitis, Chronic epidemiology, Bronchitis, Chronic etiology, Environmental Pollutants, Occupational Diseases epidemiology, Occupational Diseases etiology, Pulmonary Disease, Chronic Obstructive epidemiology, Pulmonary Disease, Chronic Obstructive etiology, Asthma epidemiology, Asthma etiology, Occupational Exposure adverse effects, Respiration Disorders, Rhinitis
- Abstract
Objectives: occupational exposure to vapours, gases, dusts and fumes (VGDF) plays an important role in the development and exacerbation of respiratory diseases. The aim of this study is to evaluate the possible association of occupational exposure to airborne pollutants and chronic respiratory diseases., Design: multicase-control study., Setting and Participants: cases of chronic respiratory diseases and controls from the Italian multicentric study Gene Environment Interaction in Respiratory Diseases (GEIRD)., Main Outcome Measures: the occurrence of rhinitis, asthma, chronic bronchitis/chronic obstructive pulmonary disease (COPD), asthma severity, spirometry data, exhaled nitric oxide (FeNO) were examined in relation to chronic and acute occupational exposures to airborne pollutants using multiple regression models., Results: 2,943 subjects were enrolled in the study. Regularm exposure to VGDF was associated with a higher prevalence of chronic bronchitis/COPD (OR 1.40, 95%CI 0.98-1.99), especially in those also having asthma (OR 1.80, 95%CI 1.14-2.85), a lower prevalence of remittent asthma (OR 0.53, 95%CI 0.29-0.96) and, in those with asthma, an increased activity of the disease (severity score) (OR 1.77, 95%CI 1.20-2.60). No associations were observed between occupational exposure and prevalence of rhinitis, spirometry and FeNO data. Finally, an association was found between acute exposure to airborne pollutants (occupational and non-occupational) and the respiratory diseases investigated, in particular active asthma and asthma associated chronic bronchitis/BPCO., Conclusions: these data confirm a significant role of occupational exposure to airborne pollutants on respiratory health, underlying the importance of workplace exposure prevention, in particular for more susceptible subjects, as those with respiratory diseases. more...
- Published
- 2023
- Full Text
- View/download PDF
48. Determinants of Anti-S Immune Response at 12 Months after SARS-CoV-2 Vaccination in a Multicentric European Cohort of Healthcare Workers-ORCHESTRA Project.
- Author
-
Leomanni L, Collatuzzo G, Sansone E, Sala E, De Palma G, Porru S, Spiteri G, Monaco MGL, Basso D, Pavanello S, Scapellato ML, Larese Filon F, Cegolon L, Mauro M, Lodi V, Lazzarotto T, Noreña I, Reinkemeyer C, Giang LTT, Fabiánová E, Strhársky J, Dell'Omo M, Murgia N, Carrasco-Ribelles LA, Violán C, Mates D, Rascu A, Vimercati L, De Maria L, Asafo SS, Ditano G, Abedini M, and Boffetta P more...
- Abstract
Background: The effectiveness of the immunity provided by SARS-CoV-2 vaccines is an important public health issue. We analyzed the determinants of 12-month serology in a multicenter European cohort of vaccinated healthcare workers (HCW)., Methods: We analyzed the sociodemographic characteristics and levels of anti-SARS-CoV-2 spike antibodies (IgG) in a cohort of 16,101 vaccinated HCW from eleven centers in Germany, Italy, Romania, Slovakia and Spain. Considering the skewness of the distribution, the serological levels were transformed using log or cubic standardization and normalized by dividing them by center-specific standard errors. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of one standard deviation of log or cubic antibody level and the corresponding 95% confidence interval (CI) for different factors and combined them in random-effects meta-analyses., Results: We included 16,101 HCW in the analysis. A high antibody level was positively associated with age (RR = 1.04, 95% CI = 1.00-1.08 per 10-year increase), previous infection (RR = 1.78, 95% CI 1.29-2.45) and use of Spikevax [Moderna] with combinations compared to Comirnaty [BioNTech/Pfizer] (RR = 1.07, 95% CI 0.97-1.19) and was negatively associated with the time since last vaccine (RR = 0.94, 95% CI 0.91-0.98 per 30-day increase)., Conclusions: These results provide insight about vaccine-induced immunity to SARS-CoV-2, an analysis of its determinants and quantification of the antibody decay trend with time since vaccination. more...
- Published
- 2023
- Full Text
- View/download PDF
49. Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project.
- Author
-
Porru S, Monaco MGL, Spiteri G, Carta A, Caliskan G, Violán C, Torán-Monserrat P, Vimercati L, Tafuri S, Boffetta P, Violante FS, Sala E, Sansone E, Gobba F, Casolari L, Wieser A, Janke C, Tardon A, Rodriguez-Suarez MM, Liviero F, Scapellato ML, dell'Omo M, Murgia N, Mates D, Calota VC, Strhársky J, Mrázová M, Pira E, Godono A, Magnano GC, Negro C, and Verlato G more...
- Subjects
- Female, Humans, Incidence, SARS-CoV-2, BNT162 Vaccine, Breakthrough Infections, Longitudinal Studies, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
Background: SARS-CoV-2 breakthrough infections (BI) after vaccine booster dose are a relevant public health issue., Methods: Multicentric longitudinal cohort study within the ORCHESTRA project, involving 63,516 health workers (HW) from 14 European settings. The study investigated the cumulative incidence of SARS-CoV-2 BI after booster dose and its correlation with age, sex, job title, previous infection, and time since third dose., Results: 13,093 (20.6%) BI were observed. The cumulative incidence of BI was higher in women and in HW aged < 50 years, but nearly halved after 60 years. Nurses experienced the highest BI incidence, and administrative staff experienced the lowest. The BI incidence was higher in immunosuppressed HW (28.6%) vs others (24.9%). When controlling for gender, age, job title and infection before booster, heterologous vaccination reduced BI incidence with respect to the BNT162b2 mRNA vaccine [Odds Ratio (OR) 0.69, 95% CI 0.63-0.76]. Previous infection protected against asymptomatic infection [Relative Risk Ratio (RRR) of recent infection vs no infection 0.53, 95% CI 0.23-1.20] and even more against symptomatic infections [RRR 0.11, 95% CI 0.05-0.25]. Symptomatic infections increased from 70.5% in HW receiving the booster dose since < 64 days to 86.2% when time elapsed was > 130 days., Conclusions: The risk of BI after booster is significantly reduced by previous infection, heterologous vaccination, and older ages. Immunosuppression is relevant for increased BI incidence. Time elapsed from booster affects BI severity, confirming the public health usefulness of booster. Further research should focus on BI trend after 4th dose and its relationship with time variables across the epidemics., (© 2023. The Author(s).) more...
- Published
- 2023
- Full Text
- View/download PDF
50. Multimorbidity and Serological Response to SARS-CoV-2 Nine Months after 1st Vaccine Dose: European Cohort of Healthcare Workers-Orchestra Project.
- Author
-
Violán C, Carrasco-Ribelles LA, Collatuzzo G, Ditano G, Abedini M, Janke C, Reinkemeyer C, Giang LTT, Liviero F, Scapellato ML, Mauro M, Rui F, Porru S, Spiteri G, Monaco MGL, Carta A, Otelea M, Rascu A, Fabiánová E, Klöslová Z, Boffetta P, and Torán-Monserrat P more...
- Abstract
Understanding antibody persistence concerning multimorbidity is crucial for vaccination policies. Our goal is to assess the link between multimorbidity and serological response to SARS-CoV-2 nine months post-first vaccine. We analyzed Healthcare Workers (HCWs) from three cohorts from Italy, and one each from Germany, Romania, Slovakia, and Spain. Seven groups of chronic diseases were analyzed. We included 2941 HCWs (78.5% female, 73.4% ≥ 40 years old). Multimorbidity was present in 6.9% of HCWs. The prevalence of each chronic condition ranged between 1.9% (cancer) to 10.3% (allergies). Two regression models were fitted, one considering the chronic conditions groups and the other considering whether HCWs had diseases from ≥2 groups. Multimorbidity was present in 6.9% of HCWs, and higher 9-months post-vaccine anti-S levels were significantly associated with having received three doses of the vaccine (RR = 2.45, CI = 1.92-3.13) and with having a prior COVID-19 infection (RR = 2.30, CI = 2.15-2.46). Conversely, lower levels were associated with higher age (RR = 0.94, CI = 0.91-0.96), more time since the last vaccine dose (RR = 0.95, CI = 0.94-0.96), and multimorbidity (RR = 0.89, CI = 0.80-1.00). Hypertension is significantly associated with lower anti-S levels (RR = 0.87, CI = 0.80-0.95). The serological response to vaccines is more inadequate in individuals with multimorbidity. more...
- Published
- 2023
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.